ANUBISMED
NDC 83021-750, HA HYALURONIC, cream, from ANUBIS COSMETICS SL.
- Product NDC
- 83021-750
- Status
- Listed
- Labeler
- ANUBIS COSMETICS SL
- Dosage form
- CREAM
- Route
- TOPICAL
- Product type
- HUMAN OTC DRUG
- Marketing category
- OTC MONOGRAPH FINAL
- Application
- M016
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/83021-750 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- ALLANTOIN.05 g/50mL
- ALOE VERA LEAF2.5 g/50mL
- FRAGRANCE 13576.225 g/50mL
- GLYCERYL MONOSTEARATE.875 g/50mL
- TROLAMINE.3 g/50mL
- BUTYLATED HYDROXYTOLUENE.0535 g/50mL
- PROPYLENE GLYCOL1.996 g/50mL
- CETYL ALCOHOL.0038 g/50mL
- TROPOLONE.004 g/50mL
- TOCOPHEROL.0004 g/50mL
- DIMETHICONE.25 g/50mL
- 1,2-HEXANEDIOL.198 g/50mL
- IMIDUREA.15 g/50mL
- CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE.25 g/50mL
- CETEARYL ETHYLHEXANOATE1.75 g/50mL
- MEDIUM-CHAIN TRIGLYCERIDES1.5 g/50mL
- CAPRYLYL GLYCOL.198 g/50mL
- OCTINOXATE3.4965 g/50mL
- GLYCERIN.4975 g/50mL
- GLYCERYL STEARATE SE1.5 g/50mL
- WATER27.4065 mL/50mL
- C12-20 ACID PEG-8 ESTER2.25 g/50mL
- OXYBENZONE2 g/50mL
- DECYL OLEATE1.9996 g/50mL
Pharmacologic classes
Allergens [CS]; Allergens [CS]; Cell-mediated Immunity [PE]; Cell-mediated Immunity [PE]; Glycerol [CS]; Increased Histamine Release [PE]; Increased Histamine Release [PE]; Increased IgG Production [PE]; Non-Standardized Chemical Allergen [EPC]; Skin Barrier Activity [PE]; Standardized Chemical Allergen [EPC]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 83021-750-50 | 83021075050 | 50 mL in 1 JAR (83021-750-50) |
Linked data
RxNorm, label and prices
RxNorm concepts
RxNorm links no concept to this product's packages.
Related lookups
No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.
Use it
Look up 83021-750 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/83021-750 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 83021-750. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.